Enhanced Compounds for Treating Coronavirus Infections

Publication ID: 24-11857517_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Compounds for Treating Coronavirus Infections,” Published Technical Disclosure No. 24-11857517_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857517_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,517.

Summary of the Inventive Concept

Improved compounds and compositions for treating coronavirus-associated diseases, offering enhanced efficacy and reduced inflammation.

Background and Problem Solved

The original patent disclosed compounds and compositions for treating coronavirus-associated diseases. However, these compounds had limitations in terms of efficacy and potential side effects. The new inventive concept addresses these limitations by introducing novel compounds and compositions that provide enhanced treatment outcomes and reduced inflammation.

Detailed Description of the Inventive Concept

The new inventive concept involves administering compounds represented by Formula I, which are further enhanced by co-administering anti-inflammatory agents, targeting the compounds to the site of protease activity using carrier molecules, or combining them with saccharide or peptide moieties as targeting agents. Additionally, the inventive concept includes pharmaceutical compositions, methods for reducing mortality and signs of inflammation, and kits for treating coronavirus-associated diseases. These enhancements improve the efficacy and safety of the original compounds, providing better treatment outcomes for patients.

Novelty and Inventive Step

The new claims introduce novel combinations of compounds and anti-inflammatory agents, targeting mechanisms, and pharmaceutical compositions that are not obvious from the original patent. These enhancements provide a significant improvement over the prior art, making the new inventive concept novel and non-obvious.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include varying the structure of the compounds, using different carrier molecules or targeting agents, or combining the compounds with other therapeutic agents. These variations would ensure broad conceptual coverage and provide opportunities for further development and improvement.

Potential Commercial Applications and Market

The enhanced compounds and compositions for treating coronavirus-associated diseases have significant commercial potential in the pharmaceutical industry, particularly in the areas of infectious disease treatment and pandemic response. The target market includes hospitals, clinics, and research institutions involved in treating and studying coronavirus-associated diseases.

CPC Classifications

Section	Class	Group
A	A61	A61K31/122
A	A61	A61K9/0053
A	A61	A61K9/0095
A	A61	A61K9/127
A	A61	A61K9/2009
A	A61	A61K9/2013
A	A61	A61K9/2018
A	A61	A61K9/2054
A	A61	A61K9/2095
A	A61	A61K9/282
A	A61	A61K9/2833
A	A61	A61K9/4833
A	A61	A61K9/4858
A	A61	A61K9/4866
A	A61	A61K31/198
A	A61	A61K31/222
A	A61	A61K31/381
A	A61	A61K31/40
A	A61	A61K31/422
A	A61	A61K31/433
A	A61	A61K31/454
A	A61	A61K31/513
A	A61	A61K31/536
A	A61	A61K36/30
A	A61	A61P31/14
A	A61	A61K2236/51

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical chemistry and medicinal drug development, specifically focused on coronavirus treatment compounds, with expertise in organic synthesis, drug delivery systems, and molecular targeting techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmaceutical sciences or medicinal chemistry, familiar with coronavirus treatment strategies, drug modification techniques, and combinatorial pharmaceutical approaches

Obviousness Rationale

A person skilled in the art would recognize that the published technical disclosure represents predictable variations of the source patent's core compound structure, utilizing standard pharmaceutical enhancement techniques such as co-administration, targeted delivery, and combination therapies that are well-established in the field of drug development. The modifications represent incremental improvements using known methodological approaches that would be apparent to a skilled practitioner seeking to optimize coronavirus treatment compounds.

Obvious Combinations & Variations

Source Patent Element

Compound represented by Formula I for treating coronavirus infections

PTD Variation

Co-administration with anti-inflammatory agents to reduce inflammatory response

Obviousness Reasoning

Combining therapeutic compounds with anti-inflammatory agents is a standard approach in treating viral infections, representing a predictable solution to managing inflammatory complications

Source Patent Element

Shikonin or glycoside of shikonin as a base compound

PTD Variation

Using carrier molecules to target compound to specific protease activity sites

Obviousness Reasoning

Targeted drug delivery using carrier molecules is a known technique in pharmaceutical development, representing a logical extension of improving compound efficacy

Source Patent Element

Base compound with potential R7 modifications

PTD Variation

Adding saccharide or peptide moieties as targeting agents

Obviousness Reasoning

Molecular targeting using saccharide and peptide moieties is a well-established strategy for improving drug specificity and reducing systemic side effects

Source Patent Element

Coronavirus treatment method using Formula I compounds

PTD Variation

Creating a treatment kit with combined anti-inflammatory agents and instructions

Obviousness Reasoning

Developing pharmaceutical kits with combination therapies and usage instructions is a standard approach in medical product development

Source Patent Element

Compounds for treating coronavirus infections

PTD Variation

Incorporating plant extracts containing shikonin derivatives to reduce mortality

Obviousness Reasoning

Using natural product derivatives to enhance pharmaceutical efficacy is a common strategy in drug development, representing an obvious approach to improving treatment outcomes

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857517 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable modifications using standard pharmaceutical development techniques. The disclosed combinations of compounds, delivery mechanisms, and therapeutic approaches would be apparent to a skilled practitioner seeking to optimize coronavirus treatment strategies, thus rendering potential patent claims obvious and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,517
Title	Compounds for treating corona virus infection
Assignee(s)	NLC Pharma Ltd